Numbers first: cagrilintide · 10 mg/mL.
I would rather over-plan the first cycle and simplify later.
I am prepared to do the work if someone can tell me which work matters.
What does a sensible plan look like, and what are the decision points?
Put another way, the arithmetic only stops being confusing once you work it through once and see that it is straightforward.
The concentration you actually work with is label claim times content fraction divided by actual diluent volume, which is usually not the same as the nominal concentration because content is usually not 100 per cent and you rarely measure the diluent volume to 0.1 mL precision.
| Vial | Diluent | Concentration | 0.25 mg | 0.5 mg | 1 mg | 2.5 mg |
|---|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 5 mg | 2 mL | 2.5 mg/mL | 10 u | 20 u | 40 u | 100 u |
| 10 mg | 1 mL | 10 mg/mL | 2.5 u | 5 u | 10 u | 25 u |
| 10 mg | 2 mL | 5 mg/mL | 5 u | 10 u | 20 u | 50 u |
| 10 mg | 3 mL | 3.33 mg/mL | 7.5 u | 15 u | 30 u | 75 u |
Units are U-100 insulin units, where 1 unit = 0.01 mL. Divide dose by concentration for millilitres, then multiply by 100.
Breaking it down further: if a 10 mg vial has 96.5 per cent content, you have 9.65 mg of peptide. Divide that by 2.00 mL and your concentration is 4.825 mg/mL, not 5.00 mg/mL, which is a 3.5 per cent systematic error in every dose calculation.
The Arrhenius relationship for drawing kinetics means that cold solution takes noticeably longer to draw than room-temperature solution.
If in doubt, use more diluent and accept the shorter usable window.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemIn practice, this is arithmetic, so let us do the arithmetic rather than argue about it.
Worked example, because the general form is easier to trust once you have seen it once. Take a 10 mg vial and add 2 mL of diluent: the concentration is 10 ÷ 2 = 5 mg/mL. A 0.5 mg dose is 0.5 ÷ 5 = 0.1 mL. On a U-100 syringe, where 1 unit = 0.01 mL, that is 0.1 ÷ 0.01 = 10 units. Change the diluent to 1 mL and the same dose becomes 5 units — same dose, half the resolution.
The rounding error accumulates if you round too many times — rounding concentration to 5.0, rounding the dose volume to 0.1 mL, rounding the unit reading to 10 — and the safest approach is to work the full precision and round only the final answer.
Published data on syringe dead space quantifies low-dead-space designs as retaining under 2 µL against 35 µL or more for conventional detachable-needle syringes.
Do the arithmetic twice, ideally with someone else doing it independently.
The single most useful thing to do is write the arithmetic on the vial label, because you will reconstruct it from memory at an inconvenient moment if you do not.
Do not use the same needle to pierce the stopper and to administer. The tip is blunted by the stopper, and the hub now contains a dose you are about to lose to dead space anyway.
Number of stopper piercings matters less than the gauge doing the piercing. A 30G or 31G needle through a butyl stopper leaves a track that reseals; a 21G or 18G drawing needle punches a core and can drop it into the solution.
The insulin-unit standard U-100 means 100 units per millilitre, so one unit is 0.01 mL — this is the conversion that trips up more people here than any other single piece of arithmetic.
Write the arithmetic on the vial label. It costs nothing and removes the step where you reconstruct it from memory.
The relevant detail is that the common error is getting the concentration right but then misreading the syringe scale, which is why checking the barrel marking rather than your memory matters.
On filtration: a 0.22 µm syringe filter will remove particulates and organisms, and it will also adsorb a fraction of your peptide onto the membrane — with a low-binding PVDF or PES membrane the loss is typically a few per cent.
The content assay results from major testing services show that nominal vial claim and measured content differ by one to ten per cent, making content a driver of dose error.
If in doubt, use more diluent and accept the shorter usable window.
The distinction that resolves most of these questions is understanding what concentration actually means and why it is not the same as label claim.
Rotation of injection site is a tolerability measure, not a pharmacokinetic one, but if you are going to do it you might as well do it right.
Worth noting: the concentration after reconstitution is not the same as the label claim, and most people do not account for the difference.
Do the arithmetic twice, ideally with someone else doing it independently.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.